Xaira Therapeutics Appoints Dr. Debbie Law as Chief Scientific Officer and Julia Tran as Chief People Officer
Xaira Therapeutics, an integrated biotechnology firm focused on leveraging AI to transform drug discovery and development, has announced the appointments of Dr. Debbie Law as Chief Scientific Officer and Julia Tran as Chief People Officer. Both will report directly to CEO Marc Tessier-Lavigne.
Dr. Law joins Xaira from Bristol Myers Squibb, where she was Senior Vice President of Nonclinical Research and Discovery Biotherapeutics. Her extensive background includes leadership roles at Janssen and Merck, as well as serving as Chief Scientific Officer at Jounce Therapeutics and Ablynx NV. She earned her Doctor of Philosophy (DPhil) in immunology from the University of Oxford and completed postdoctoral studies at UCSF.
Julia Tran most recently held the position of Chief People Officer at Graphite Bio. With over 25 years of experience, she has been instrumental in scaling biotech and tech companies through various growth phases, including IPOs and M&A activities. Her previous roles include significant HR positions at Millennium Pharmaceuticals, Amyris Biotechnologies, and CV Therapeutics.
Xaira launched in April with a mission to revolutionize medicine discovery through the application of advanced AI technologies. Co-founded by Nobel Laureate Dr. David Baker, the company has attracted over $1 billion in committed capital from leading investors, including ARCH Venture Partners and Foresite Capital.
“We’ve made significant strides since our launch,” said Tessier-Lavigne. “The addition of Debbie and Julia to our leadership team marks an important step forward, and I’m excited to work alongside such talented individuals.”
With a focus on developing AI-driven solutions for drug design and clinical applications, Xaira aims to bridge the gap between biological targets and engineered therapies, enhancing patient care through innovative technologies.
About Xaira Therapeutics
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
